Industry
Biotechnology
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Loading...
Open
8.37
Mkt cap
560M
Volume
2.2M
High
8.50
P/E Ratio
-4.46
52-wk high
12.22
Low
7.63
Div yield
N/A
52-wk low
4.66
Portfolio Pulse from
February 14, 2025 | 8:45 pm
Portfolio Pulse from
January 07, 2025 | 7:45 pm
Portfolio Pulse from
December 24, 2024 | 4:45 pm
Portfolio Pulse from
November 10, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 5:41 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 2:19 pm
Portfolio Pulse from Juan Spínelli
September 05, 2024 | 4:53 pm
Portfolio Pulse from Benzinga Newsdesk
August 29, 2024 | 12:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.